Literature DB >> 10359051

Circumvention of 5-fluorouracil resistance in human stomach cancer cells by uracil phosphoribosyltransferase gene transduction.

M Inaba1, H Sawada, A Sadata, H Hamada.   

Abstract

A human stomach cancer cell line with acquired resistance to 5-fluorouracil (5-FU), NUGC-3/5FU/ L, has been found to possess reduced ability to convert 5-FU into active metabolites. We attempted in vitro gene therapy for this 5-FU-resistant cell line. NUGC-3 and NUGC-3/5FU/L cells were infected with recombinant adenovirus (Ad) containing Escherichia coli uracil phosphoribosyltransferase (UPRT) gene driven by CAG promoter (CA), AdCA-UPRT, and changes in their 5-FU metabolism and sensitivity were investigated. Activities of orotate phosphoribosyltransferase increased from 10.2 and 1.56 (nmol/mg protein/30 min) in the uninfected cells of NUGC-3 and NUGC-3/5FU/L to 216 and 237, respectively, after the transfection of UPRT gene. The 5-FU nucleotide level in the acid-insoluble fraction increased from 7.32 to 15.9 (pmol/mg protein) in NUGC-3 cells on infection with AdCA-UPRT, and in NUGC-3/5FU/L cells it increased from 1.91 to 21.4. The 50% growth-inhibition concentration (IC50) was 12.7 micromol/liter for NUGC-3 and much higher than 100 micromol/liter for NUGC-3/5FU/L, indicating over 8-fold resistance. NUGC-3/ SFU/L transfected with the UPRT gene showed very high sensitivity to 5-FU with an IC50 of 3.2 micromol/liter. The high resistance in this metabolic activation-deficient cell line was thus completely reversed by transduction of an exogenous gene coding for a 5-FU-anabolizing enzyme.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10359051      PMCID: PMC5926061          DOI: 10.1111/j.1349-7006.1999.tb00754.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


adenovirus containing lacZ gene driven by CAG promoter adenovirus containing UPRT gene driven by CAG promoter 1‐β‐d‐arabinofuranosylcytosine Escherichia coli 5‐fluoro‐2′‐deoxyuridylate 5‐fluorouracil 5‐fluorouridine‐5′‐triphosphate β‐galactosidase 50% growth‐inhibition concentration multiplicity of infection 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide orotate phosphoribosyltransferase phosphate‐buffered saline 5‐phosphoribosyl‐1‐pyrophosphate thymidylate synthase uracil phosphoribosyltransferase 5‐fluorouridylate
  25 in total

1.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Authors:  M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

2.  Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity.

Authors:  D M Hapke; A P Stegmann; B S Mitchell
Journal:  Cancer Res       Date:  1996-05-15       Impact factor: 12.701

Review 3.  Gene therapy for cancer: what have we done and where are we going?

Authors:  J A Roth; R J Cristiano
Journal:  J Natl Cancer Inst       Date:  1997-01-01       Impact factor: 13.506

Review 4.  Ara-C: cellular and molecular pharmacology.

Authors:  S Grant
Journal:  Adv Cancer Res       Date:  1998       Impact factor: 6.242

5.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.

Authors:  C G Leichman; H J Lenz; L Leichman; K Danenberg; J Baranda; S Groshen; W Boswell; R Metzger; M Tan; P V Danenberg
Journal:  J Clin Oncol       Date:  1997-10       Impact factor: 44.544

6.  Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro.

Authors:  T Tanaka; F Kanai; S Okabe; Y Yoshida; H Wakimoto; H Hamada; Y Shiratori; K Lan; M Ishitobi; M Omata
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

7.  Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes.

Authors:  G J Peters; E Laurensse; A Leyva; J Lankelma; H M Pinedo
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

8.  Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules.

Authors:  C Aschele; A Sobrero; M A Faderan; J R Bertino
Journal:  Cancer Res       Date:  1992-04-01       Impact factor: 12.701

9.  Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells.

Authors:  M Inaba; J Mitsuhashi
Journal:  Oncol Res       Date:  1994       Impact factor: 5.574

10.  Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells.

Authors:  M Inaba; J Mitsuhashi; H Sawada; N Miike; Y Naoe; A Daimon; K Koizumi; H Tsujimoto; M Fukushima
Journal:  Jpn J Cancer Res       Date:  1996-02
View more
  2 in total

1.  Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect.

Authors:  Katalin Lumniczky; Géza Sáfrány
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

2.  Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.

Authors:  Kotaro Miyake; Satoru Imura; Tomoharu Yoshizumi; Tetsuya Ikemoto; Yuji Morine; Mitsuo Shimada
Journal:  Int J Clin Oncol       Date:  2007-04-27       Impact factor: 3.402

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.